Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

被引：0

作者：

Ducreux, M. P. ^{[1
]}

Cheng, A-L. ^{[2
]}

Qin, S. ^{[3
]}

Zhu, A. X. ^{[4
]}

Ikeda, M. ^{[5
]}

Kim, T-Y. ^{[6
]}

Xu, D-Z. ^{[7
]}

Verret, W. ^{[8
]}

Liu, J. ^{[7
]}

Finn, R. S. ^{[9
]}

Galle, P. R. ^{[10
]}

机构：

[1] Gustave Roussy, Med Oncol, Villejuif, France

[2] Natl Taiwan Univ Hosp, Med Oncol, Taipei, Taiwan

[3] Peoples Liberat Army Canc Ctr, Med Oncol, Nanjing, Jiangsu, Peoples R China

[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[5] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[6] Seoul Natl Univ, Med Oncol, Coll Med, Seoul, South Korea

[7] F Hoffman La Roche Ltd, Roche Prod Dev, Shanghai, Peoples R China

[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[9] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA

[10] Univ Med Ctr Mainz, Med Dept 1, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

782TiP

引用

页码：267 / 267

页数：1

共 50 条

[41] Atezolizumab plus bevacizumab combination therapy compared to sorafenib and atezolizumab monotherapies for treatment of unresectable or metastatic hepatocellular carcinoma
Ahmed, Faiza
Guntipalli, Prathima
Yukselen, Zeynep
Coronel, Maria-Kassandra
Zaidi, Madiha
Onwumeh-Okwundu, Jennifer
Garimella, Vamsi
Gudapati, Sravya
Mezidor, Marc-Darlene
Andrews, Kim
Mouchli, Mohamad
Shahini, Endrit
Mohan, Karthik
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 69 - 70
[42] Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Nishikawa, Hiroki
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Koshiyama, Yuichi
Toyoda, Hidenori
Ogawa, Chikara
Hatanaka, Takeshi
Kakizaki, Satoru
Kawata, Kazuhito
Ohama, Hideko
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Nishimura, Takashi
Imai, Michitaka
Kosaka, Hisashi
Naganuma, Atsushi
Matono, Tomomitsu
Aoki, Tomoko
Kuroda, Hidekatsu
Yata, Yutaka
Koizumi, Yohei
Nakamura, Shinichiro
Enomoto, Hirayuki
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 233 - 245
[43] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
Tsilimigras, Diamantis I.
Moris, Dimitrios
JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
[44] Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
Sho, Takuya
Suda, Goki
Yamamoto, Yoshiya
Furuya, Ken
Baba, Masaru
Ogawa, Koji
Kubo, Akinori
Tokuchi, Yoshimasa
Fu, Qingjie
Yang, Zijian
Kimura, Megumi
Kitagataya, Takashi
Maehara, Osamu
Ohnishi, Shunsuke
Nakamura, Akihisa
Yamada, Ren
Ohara, Masatsugu
Kawagishi, Naoki
Natsuizaka, Mitsuteru
Nakai, Masato
Suzuki, Kazuharu
Izumi, Takaaki
Meguro, Takashi
Terashita, Katsumi
Takagi, Tomofumi
Ito, Jun
Kobayashi, Tomoe
Miyagishima, Takuto
Sakamoto, Naoya
CANCERS, 2022, 14 (16)
[45] IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
Hack, Stephen P.
Spahn, Jessica
Chen, Minshan
Cheng, Ann-Lii
Kaseb, Ahmed
Kudo, Masatoshi
Lee, Han Chu
Yopp, Adam
Chow, Pierce
Qin, Shukui
FUTURE ONCOLOGY, 2020, 16 (15) : 975 - 989
[46] COST EFFECTIVENESS MODEL OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC) IN FRENCH SETTING
de Gennes, Dubois C.
Mazaleyrat, B.
Alvarez, Sanchez J.
Lueza, B.
VALUE IN HEALTH, 2022, 25 (01) : S69 - S69
[47] HEPATIC EVENTS AND VIRAL KINETICS IN PATIENTS (PTS) WITH HEPATITIS B/C VIRUS (HBV/HCV)-RELATED, UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) OR SORAFENIB (SOR) IN IMbrave150
Hsu, Chiun
Ducreux, Michel
Zhu, Andrew X.
Qin, Shukui
Ikeda, Masafumi
Kim, Tae-You
Galle, Peter R.
Finn, Richard
Chen, Ethan
Shao, Hui
Stanzel, Sven Franz
Xu, Derek-Zhen
Cheng, Ann-Lii
HEPATOLOGY, 2020, 72 : 779A - 780A
[48] IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
Ducreux, Michel
Zhu, Andrew X.
Cheng, Ann-Lii
Galle, Peter R.
Ikeda, Masafumi
Nicholas, Alan
Verret, Wendy
Li, Lindong
Gaillard, Vincent E.
Lencioni, Riccardo
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Predictive genomic biomarkers for atezolizumab plus bevacizumab combination immunotherapy response in liver cancer: Insights from the IMbrave150 trial
Lee, Ju-Seog
Yim, Sun Young
Baek, Seung-Woo
Lee, Sung Hwan
Sohn, Bohwa
Jeong, Seong
Kang, Sanghee
Park, Kena
Park, Hyewon
Lee, Sunyoung S.
Kaseb, Ahmed O.
Kim, Ji Hoon
Chu, In-Sun
CANCER RESEARCH, 2024, 84 (07)
[50] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
Cappuyns, Sarah
Pique-Gili, Marta
Esteban-Fabro, Roger
Philips, Gino
Pinyol, Roser
Vandecaveye, Vincent
Abril-Fornaguera, Jordi
Haber, Philipp
Verslype, Chris
Van Cutsem, Eric
Lambrechts, Diether
Villanueva, Augusto
Dekervel, Jeroen
Llovet, Josep M.
HEPATOLOGY, 2023, 78 : S1871 - S1872

← 1 2 3 4 5 →